Analysis of recurrent events in patients receiving ticagrelor or clopidogrel for ACS in the PLATO study

Source: Circulation Area: News According to an analysis of recurrent events in the PLATO study, ticagrelor reduces both the first and recurrent cardiovascular events in patients with acute coronary syndrome (ACS) compared with clopidogrel. Although it is associated with a slightly increased risk of having a first non-CABG major bleed, the bleeding risk appears to be similar to clopidogrel thereafter.    The authors note that censoring patients after the first occurrence of any primary endpoint event in clinical trials limits the information available on the effect of therapy on subsequent events, and leaves questions about overall efficacy and risks of continued therapy unanswered. The purpose of their analysis was to use data from the PLATO study to determine the effect of ticagrelor, as compared with clopidogrel, on total (first and recurrent) cardiovascular events in patients with acute coronary syndrome (ACS).   The PLATO study randomised patients presenting with ACS to ticagrelor ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news